{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T22:48:56Z","timestamp":1789858136923,"version":"4.0.1"},"reference-count":47,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,9]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>To provide an overview of recently published studies on pathogenesis and management of juvenile idiopathic arthritis (JIA).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>In the past year, the potential role of network analysis in the understanding of the molecular phenotype of individual JIA subgroups has been highlighted. In addition, potential new targets for pharmacologic interventions have been identified through the elucidation of mechanisms that modulate the function of cells involved in the inflammatory process. There is a growing interest for the role of the gut microbiome in disease pathogenesis, which may open the way to future therapeutic manipulations of fecal microbial population. Recent therapeutic studies have provided important information in large patient samples on the effectiveness and toxicity profile of biologic medications used in JIA. Concomitant administration of methotrexate was found to increase the effectiveness of intra-articular corticosteroid therapy in children with oligoarticular JIA.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>A great deal of work is being conducted to better define the molecular phenotype of the individual subsets of JIA and to identify potential new targets for therapeutic interventions. The results of the ongoing large-scale international data collections will help establish the long-term safety profiles of biologic medications, in particular the risk of malignancy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000417","type":"journal-article","created":{"date-parts":[[2017,5,23]],"date-time":"2017-05-23T22:38:36Z","timestamp":1495579116000},"page":"523-529","source":"Crossref","is-referenced-by-count":50,"title":["Update on the pathogenesis and treatment of juvenile idiopathic arthritis"],"prefix":"10.1097","volume":"29","author":[{"given":"Gabriella","family":"Giancane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Alongi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Ravelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230829","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1016\/S0140-6736(11)60244-4","article-title":"Juvenile idiopathic arthritis","volume":"377","author":"Prakken","year":"2011","journal-title":"Lancet"},{"key":"R2-20230829","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(07)60363-8","article-title":"Juvenile idiopathic arthritis","volume":"369","author":"Ravelli","year":"2007","journal-title":"Lancet"},{"key":"R3-20230829","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1517\/14728214.2011.581662","article-title":"Emerging drugs to treat juvenile idiopathic arthritis","volume":"16","author":"Ruperto","year":"2011","journal-title":"Expert Opin Emerg Drugs"},{"key":"R4-20230829","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1002\/acr.21973","article-title":"It is worth including assessment of disease activity state in juvenile arthritis clinical trials","volume":"65","author":"Consolaro","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R5-20230829","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1002\/art.34343","article-title":"Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis","volume":"64","author":"Wallace","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R6-20230829","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1002\/art.38615","article-title":"Review: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis?","volume":"66","author":"Nigrovic","year":"2014","journal-title":"Arthritis Rheumatol (Hoboken)"},{"key":"R7-20230829","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12969-016-0078-4","article-title":"Network analysis and juvenile idiopathic arthritis (JIA): a new horizon for the understanding of disease pathogenesis and therapeutic target identification","volume":"14","author":"Donn","year":"2016","journal-title":"Pediatr Rheumatol"},{"key":"R8-20230829","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1136\/annrheumdis-2012-201388","article-title":"It is time to rethink juvenile idiopathic arthritis classification and nomenclature","volume":"71","author":"Martini","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"R9-20230829","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/art.30076","article-title":"Antinuclear antibody-positive patients should be grouped as a separate category in the classification of juvenile idiopathic arthritis","volume":"63","author":"Ravelli","year":"2011","journal-title":"Arthritis Rheum"},{"key":"R10-20230829","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12969-016-0075-7","article-title":"Familial autoimmunity in the childhood arthritis and rheumatology research alliance registry","volume":"14","author":"Prahalad","year":"2016","journal-title":"Pediatr Rheumatol"},{"key":"R11-20230829","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1093\/rheumatology\/ket314","article-title":"The genetics of juvenile idiopathic arthritis: current understanding and future prospects","volume":"53","author":"Cobb","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"R12-20230829","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1136\/annrheumdis-2016-210025","article-title":"Fine-mapping the MHC locus in juvenile idiopathic arthritis (JIA) reveals genetic heterogeneity corresponding to distinct adult inflammatory arthritic diseases","volume":"76","author":"Hinks","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R13-20230829","first-page":"1900","article-title":"Are the number of joints involved or the presence of psoriasis still useful tools to identify homogeneous disease entities in juvenile idiopathic arthritis?","volume":"30","author":"Martini","year":"2003","journal-title":"J Rheumatol"},{"key":"R14-20230829","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/art.20945","article-title":"Patients with antinuclear antibody-positive juvenile idiopathic arthritis constitute a homogeneous subgroup irrespective of the course of joint disease","volume":"52","author":"Ravelli","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"(5 Suppl 93)","key":"R15-20230829","first-page":"S40","article-title":"The conundrum of juvenile psoriatic arthritis","volume":"33","author":"Ravelli","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"R16-20230829","doi-asserted-by":"crossref","first-page":"15970","DOI":"10.1073\/pnas.1520779112","article-title":"HLA-DRB1\u221711 and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis","volume":"112","author":"Ombrello","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"R17-20230829","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1136\/annrheumdis-2016-210324","article-title":"Genetic architecture distinguishes systemic juvenile idiopathic arthritis from other forms of juvenile idiopathic arthritis: clinical and therapeutic implications","volume":"76","author":"Ombrello","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R18-20230829","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.clim.2015.12.011","article-title":"Altered signaling in systemic juvenile idiopathic arthritis monocytes","volume":"163","author":"Macaubas","year":"2016","journal-title":"Clin Immunol"},{"key":"R19-20230829","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1002\/art.39694","article-title":"Monocyte microRNA expression in active systemic juvenile idiopathic arthritis implicates miR-125a-5p in polarized monocyte phenotypes","volume":"68","author":"Schulert","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"R20-20230829","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/art.39933","article-title":"Inflammatory gene expression profile and defective interferon-\u03b3 and granzyme k in natural killer cells from systemic juvenile idiopathic arthritis patients","volume":"69","author":"Put","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"R21-20230829","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1002\/art.39606","article-title":"Next-generation sequencing reveals restriction and clonotypic expansion of Treg cells in juvenile idiopathic arthritis","volume":"68","author":"Henderson","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"R22-20230829","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1136\/annrheumdis-2015-208992","article-title":"TCR repertoire sequencing identifies synovial Treg cell clonotypes in the bloodstream during active inflammation in human arthritis","volume":"76","author":"Rossetti","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R23-20230829","doi-asserted-by":"crossref","first-page":"5616","DOI":"10.4049\/jimmunol.1500391","article-title":"Synovial regulatory T cells occupy a discrete TCR niche in human arthritis and require local signals to stabilize FOXP3 protein expression","volume":"195","author":"Bending","year":"2015","journal-title":"J Immunol"},{"key":"R24-20230829","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/cei.12900","article-title":"Gut microbiome in children with enthesitis-related arthritis in a developing country and the effect of probiotic administration","volume":"187","author":"Aggarwal","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"R25-20230829","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.3389\/fmicb.2016.01703","article-title":"Alteration of fecal microbiota profiles in juvenile idiopathic arthritis. Associations with HLA-B27 allele and disease status","volume":"7","author":"Di Paola","year":"2016","journal-title":"Front Microbiol"},{"key":"R26-20230829","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s10096-015-2548-x","article-title":"Faecal microbiome in new-onset juvenile idiopathic arthritis","volume":"35","author":"Tejesvi","year":"2016","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"R27-20230829","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1542\/peds.2015-0036","article-title":"Antibiotic exposure and juvenile idiopathic arthritis: a case-control study","volume":"136","author":"Horton","year":"2015","journal-title":"Pediatrics"},{"key":"R28-20230829","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12969-016-0104-6","article-title":"Gut microbiota-host interactions and juvenile idiopathic arthritis","volume":"14","author":"Arvonen","year":"2016","journal-title":"Pediatr Rheumatol"},{"key":"R29-20230829","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.semarthrit.2016.07.001","article-title":"Biological agents in polyarticular juvenile idiopathic arthritis: a meta-analysis of randomized withdrawal trials","volume":"46","author":"Amarilyo","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"R30-20230829","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s13075-016-1170-3","article-title":"Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab","volume":"18","author":"Horneff","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"R31-20230829","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1136\/annrheumdis-annrheumdis-2014-206747","article-title":"Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA)","volume":"75","author":"Klotsche","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R32-20230829","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.jpeds.2013.03.047","article-title":"Methotrexate therapy may prevent the onset of uveitis in juvenile idiopathic arthritis","volume":"163","author":"Papadopoulou","year":"2013","journal-title":"J Pediatr"},{"key":"R33-20230829","first-page":"714","article-title":"Methotrexate treatment may prevent uveitis onset in patients with juvenile idiopathic arthritis: experiences and subgroup analysis in a cohort with frequent methotrexate use","volume":"34","author":"Kostik","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"R34-20230829","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/acr.22961","article-title":"Risk of serious infection in juvenile idiopathic arthritis patients associated with tumor necrosis factor inhibitors and disease activity in the German biologics in pediatric rheumatology registry","volume":"69","author":"Becker","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R35-20230829","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.semarthrit.2016.10.008","article-title":"Efficacy of biologic therapy across individual juvenile idiopathic arthritis subtypes: a systematic review","volume":"46","author":"Davies","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"R36-20230829","doi-asserted-by":"crossref","first-page":"467","DOI":"10.3389\/fphar.2016.00467","article-title":"IL-1 inhibition in systemic juvenile idiopathic arthritis","volume":"7","author":"Giancane","year":"2016","journal-title":"Front Pharmacol"},{"key":"R37-20230829","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1002\/acr.22903","article-title":"Cost-effectiveness analysis of first-line treatment with biologics in polyarticular juvenile idiopathic arthritis","volume":"68","author":"Luca","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R38-20230829","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/rheumatology\/kev434","article-title":"Factors associated with improvement in disease activity following initiation of etanercept in children and young people with Juvenile Idiopathic Arthritis: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study","volume":"55","author":"Kearsley-Fleet","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"R39-20230829","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12969-016-0126-0","article-title":"Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept. Pediatr Rheumatol","volume":"14","author":"Verazza","year":"2016","journal-title":"Pediatric Rheumatology"},{"key":"R40-20230829","doi-asserted-by":"crossref","first-page":"816","DOI":"10.3899\/jrheum.150430","article-title":"Two-year efficacy and safety of etanercept in pediatric patients with extended oligoarthritis, enthesitisrelated arthritis, or psoriatic arthritis","volume":"43","author":"Constantin","year":"2016","journal-title":"J Rheumatol"},{"key":"R41-20230829","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1136\/annrheumdis-2015-207818","article-title":"Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan","volume":"75","author":"Yokota","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R42-20230829","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","article-title":"Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial","volume":"371","author":"Yokota","year":"2008","journal-title":"Lancet"},{"key":"R43-20230829","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","article-title":"Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis","volume":"367","author":"De Benedetti","year":"2012","journal-title":"N Engl J Med"},{"key":"R44-20230829","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/gene.2012.3","article-title":"Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment","volume":"13","author":"Ravelli","year":"2012","journal-title":"Genes Immun"},{"key":"R45-20230829","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/art.39407","article-title":"Rate and clinical presentation of macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with canakinumab","volume":"68","author":"Grom","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"R46-20230829","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0140-6736(17)30180-0","article-title":"The value of old drugs for juvenile idiopathic arthritis","volume":"389","author":"Wulffraat","year":"2017","journal-title":"Lancet"},{"key":"R47-20230829","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/S0140-6736(17)30065-X","article-title":"Intra-articular corticosteroids versus intra-articular corticosteroids plus methotrexate in oligoarticular juvenile idiopathic arthritis: a multicentre, prospective, randomised, open-label trial","volume":"389","author":"Ravelli","year":"2017","journal-title":"Lancet"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00002281-201709000-00015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T06:47:39Z","timestamp":1693291659000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-201709000-00015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000417","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9]]}}}